reports
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thomas Vranken
mdxhealth Strong growth outlook (Model Update)
Following mdxhealth's 1H24 results, we updated our model to incorporate the new segment reporting. Overall, our topline estimates remain largely unchanged, as we remain optimistic on the company's long-term growth perspectives. We have slightly adjusted our FY24 gross margin estimates downward, but maintain confidence in adjusted EBITDA profitability by 1H25. Our new TP lands at $ 5.70 (previously $ 6.00), while we reiterate a Buy rating.
- Guy Sips
- Hilde Van Boxstael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
mdxhealth FIRST LOOK: 1H24 results continue impressive topline growth
In line with previously reported preliminary results, mdxhealth's 1H24 results feature a strong +32% y/y uptake in revenues, while cash burn gradually comes down. Management reiterates its recently upped $ 85-87m FY24 revenue guidance and it still foresees adjusted EBITDA profitability by 1H25. We see mdxhealth as a uniquely positioned player in the urology diagnostics space, and reiterate a $ 6.0 TP and Buy rating.
MDxHealth Reports Q2 and Half Year 2024 Results
MDxHealth Reports Q2 and Half Year 2024 Results MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 millionYear-over-year H1 revenues increase by 34% to 42.0 millionConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the second quarter and half year ended June 30, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: “Our str...
MDxHealth to Present Second Quarter and First Half 2024 Financial Resu...
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 () – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and six-month period ended June 30, 2024, after market close on Wedne...
- Jacob Mekhael
- Kristof Samoy
- Thomas Vranken
- Thomas Vranken
mdxhealth Feedback from strong preliminary Q2 results
mdxhealth's preliminary 2Q24 results feature a continued strong uptake in revenues to $ 22.2m (+32% y/y) driven by consistent growth across the product portfolio. On the back of this strong growth, management again raised its FY24 revenue guidance to $ 85-87m i.e., 23% growth y/y. The company expresses confidence in reaching adjusted EBITDA profitability in 1H25. We maintain our $ 6 TP and re-iterate our Buy rating.
- Thomas Vranken
mdxhealth Strong preliminary Q2 results trigger guidance upgrade
mdxhealth's preliminary 2Q24 results feature a continued strong uptake in revenues to $ 22.2m (+32% y/y). We presume the new germline test has started contributing revenue as of Q2 as planned, and on the back of strong growth prospects management again raised its FY24 revenue guidance to $ 85-87m i.e., 23% growth y/y. The company expresses confidence in reaching adjusted EBITDA profitability in 1H25. We maintain our $ 6 TP and re-iterate our Buy rating.
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 year...
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raise...
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenuesand Raises 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 () – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary Q2 and half year 2024 revenues and cash. The Company expects to report Q2 and half year 2024 revenues of approximately $22.2 and $42.0 million, respectively, representing year-over-year growth of 32% and 34%, respectively, and represen...
- Jacob Mekhael
- Thomas Vranken
Mdxhealth to Present at Upcoming Investor Conferences
Mdxhealth to Present at Upcoming Investor Conferences Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 () – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024. William Blair 44th Annual Growth Stock ConferencePresentation: Wednesday, June 5, at 5:00pm ETWebcast: Jefferies Global Healthcare ConferencePresentation: Thursday, June 6, at 1:30pm ETWebcast: Live w...
- Thomas Vranken
mdxhealth 1Q24 update reveal strong rev growth and refinanced debt fac...
mdxhealth's 1Q24 results feature a continued strong uptake in revenues to $ 19.8m (+35% y/y), supported by 16% growth in prostate test volume. The company expects the new germline test to start contributing revenue as of Q2, and on the back of strong growth prospects across the menu raises its FY24 rev guidance to $ 83-85m (prev. $ 79-81m). mdxhealth also refinanced its existing debt through a new $ 100m facility with OrbiMed, replacing the existing Innovatus loan and bringing in $ 20m new cash....
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from Or...
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2024 an...
- Thomas Vranken
mdxhealth FIRST LOOK: New test added to the menu
mdxhealth continues its growth trajectory as it adds a non-invasive prostate cancer test for risk stratification to its test menu. We deem the asset to be relatively mature as NCCN guidelines and reimbursement are already in place, allowing for topline contribution as of 2H24. Management confirmed no balance sheet impact and no additional capabilities need to be developed. We plan to incorporate the test in a future iteration of our model, and for now maintain our $ 6.0 TP and Buy rating.
- Guy Sips
- Thomas Vranken
- Wim Hoste
- Hilde Van Boxstael
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
mdxhealth FY23 shows solid growth, cautious FY24 outlook reiterated
In line with previously reported highlights, mdxhealth's FY23 results feature a strong +89% y/y uptake in revenues (42% excl. GPS), while cash burn gradually comes down. Management reiterates its $ 79-81m FY24 revenue guidance and stresses operating discipline as it foresees adjusted EBITDA profitability by 1H25. Furthermore, the company flags multiple, high-growth opportunities that could strengthen the existing menu. Given the cautious FY24 topline guidance, we have adjusted our mid-term topli...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.